The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS on the first day of each month.

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity. 

The following financial relationships have been provided:

Elaine Siegfried, MD (Chair)
Consultant: AbbVie, Arcutis, Dermavant, NobelPharma, Novan, Regeneron, Sanofi, Verrica
Data and Safety Monitoring Board: Amgen, Incyte, Janssen, Leo, Nova, Pierre Fabre/Edelife, Pfizer, UCB
Grants/Research Support: Amgen, Pfizer, Regeneron, Sanofi, Verrica
Speakers' Bureau: Regeneron, Sanofi, Verrica

Adelaide Hebert, MD (Faculty)
Consultant: Arcutis, Dermavant/Organon, Galderma, Incyte, Lilly, Pfizer, Takeda
Grants/Research Support: AbbVie, Amgen, Arcutis, Deermavant/Organonon, Incyte, Janssen, Oneness, Pfizer, Sanofi
Speakers' Bureau: Arcutis, Dermavant/Organon, Galderma, Incyte, Lilly, Pfizer, Takeda

Bob Geng, MD (Faculty)
Consultant: Amgen, Arcutis,Eli Lilly, Galderma, Incyte, Leo, Pfizer, Regeneron, Sanofi
Grants/Research Support: Amgen, Arcutis, Eli Lilly, Incyte, Leo, Organon, Pfizer, Regeneron, Sanofi
Speakers' Bureau: AbbVie, Amgen, Eli Lilly, Galderma, Incyte, Leo, Pfizer, Regeneron, Sanofi

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

This activity will take approximately 255 minutes to complete. To receive credit, learners are required to complete the preassessment, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact McKenna Reinhard at [email protected].

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: baricitinib, methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil are not approved by the US Food and Drug Administration for the treatment of atopic dermatitis. Abrocitinib and upadacitinib are not approved by the US Food and Drug Administration for first-line systemic treatment of atopic dermatitis.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.